• Crizotinib Hydrochloride in ALK Research

  2026-09-20

  Crizotinib hydrochloride is an ATP-competitive ALK kinase inhibitor that also targets c-Met and ROS1. Its defined kinase mechanism makes it useful for cancer biology research, while patient-derived assembloid studies show why stromal context must be measured when interpreting drug response.

• NADH Redox Mapping: From Coenzyme to Assay

  2026-09-19

  NADH is more than an electron donor: its ratio with NAD⁺ can reveal how cells allocate metabolic and respiratory capacity. This guide translates redox biology into practical assay decisions, disease-model applications, and evidence-based handling of research-grade reduced nicotinamide adenine dinucleotide.

• Elbasvir–Grazoprevir in Hepatitis C

  2026-09-18

  The reference review evaluates elbasvir–grazoprevir as a dual direct-acting antiviral regimen, integrating NS5A and NS3/4A inhibition with pharmacokinetic, efficacy, resistance, and safety evidence. Its main practical conclusion is that the fixed-dose combination is particularly well supported for HCV genotypes 1 and 4, including selected patients with cirrhosis, HIV/HCV coinfection, or advanced renal impairment.

• (5Z)-7-Oxozeaenol: TAK1 and Stress Signaling

  2026-09-18

  A translational framework for using (5Z)-7-Oxozeaenol to separate TAK1-dependent inflammatory signaling from AMPK–SQSTM1 metabolic adaptation, with practical guidance for mechanism-focused studies.

• Jiedu Xiaozheng Yin in Colitis-Associated Colorectal Cancer

  2026-09-17

  The reference study shows that Jiedu Xiaozheng Yin limits colitis-associated colorectal cancer progression by shifting intestinal macrophages toward an M1-like phenotype through TLR4-linked signaling. Its integrated mouse and RAW264.7-cell experiments connect reduced tumor burden with changes in inflammatory markers, phagocytosis, and M1/M2 polarization, while pharmacologic pathway perturbation provides mechanistic support.

• Bay 11-7085: NF-κB Workflow Guide

  2026-09-17

  Bay 11-7085 provides a practical chemical route for testing how NF-κB signaling connects inflammatory stimulation with cell-cycle arrest and apoptosis. This guide translates its mechanism into reproducible cell assays, endometriosis and meningitis applications, and an ER-stress-informed neuroinflammation workflow.

• Tin Mesoporphyrin IX: A Causal HO-1 Probe

  2026-09-16

  Tin Mesoporphyrin IX (chloride) enables causal interrogation of heme oxygenase signaling rather than simple pathway correlation. This article connects its biochemical selectivity with HO-1/ROS findings in hepatitis B research and outlines assay decisions for metabolic disease research.

• I-BET-762: BET Inhibitor for Ferroptosis

  2026-09-16

  I-BET-762 is a selective BET inhibitor that connects epigenetic control with ferroptosis susceptibility. This article translates BRD4, ROS, and FSP1 findings into practical assay decisions for inflammation and cancer biology research.

• Palmitic acid (N2456): Protocol and QC Guide

  2026-09-15

  Palmitic acid (hexadecanoic acid, SKU N2456) provides a defined saturated long-chain fatty acid input for solvent-based studies of lipid metabolism, insulin signaling, inflammation, and protein palmitoylation. It is insoluble in water and is not intended for direct aqueous addition or long-term solution storage, so fresh preparation, solvent controls, and documented QC are essential.

• Grazoprevir/Elbasvir: Evidence from HCV Literature

  2026-09-15

  The reference review explains how combining the NS3/4A protease inhibitor grazoprevir with the NS5A inhibitor elbasvir created a potent interferon-free strategy for chronic HCV infection. Its main practical contribution is the integration of efficacy, safety, resistance, pharmacology, and difficult-to-treat subgroup evidence into a framework for interpreting genotype- and patient-specific treatment decisions.

• APOL1 Evolution, Isoforms, and APOL3 Interaction

  2026-09-14

  The 2025 Cells study integrates population genetics, splice-isoform biology, and APOL1–APOL3 interaction analysis to refine models of APOL1-associated cellular injury. Its main contribution is a multidomain framework showing why renal toxicity cannot be interpreted from APOL1 risk variants alone, without considering haplotype context, isoform identity, and protein partners.

• Quizartinib (AC220) FLT3 Assay Workflows

  2026-09-14

  Build cleaner FLT3-dependent AML experiments with Quizartinib (AC220), from low-nanomolar pathway inhibition to translational xenograft studies. This guide emphasizes dosing logic, phospho-FLT3 readouts, resistance modeling, and troubleshooting for reproducible results.

• BMS-345541 hydrochloride: IKK Assay Guide

  2026-09-13

  Use BMS-345541 hydrochloride as a selective IKK inhibitor to separate NF-κB-dependent inflammatory signaling from downstream cell-death phenotypes. This workflow combines concentration, solubility, timing, and orthogonal readout guidance for inflammation research, T-ALL models, and RIPK1-focused experiments.

• Artemisinin, NRF2, and Ferroptosis in Diabetic Cognition

  2026-09-12

  Wang et al. showed that artemisinin improved learning and memory in streptozotocin-induced type 2 diabetes mellitus mice while reducing hippocampal oxidative injury and ferroptosis-related changes. Pharmacological blockade of NRF2 with ML385 and induction of ferroptosis with erastin weakened these benefits, supporting an NRF2-dependent mechanism that links redox control to diabetic cognitive dysfunction.

• Bromodomain Inhibitor, (+)-JQ1: Assay Guide

  2026-09-11

  A practical, scenario-based guide to using Bromodomain Inhibitor, (+)-JQ1 (SKU A1910) in viability, proliferation, and apoptosis workflows. It connects BET biology with solvent control, time-course design, endpoint selection, data interpretation, and research-grade product selection.

8211 records 5/548 page Previous Next 12345 下5页 Last page